$15.90▼-0.18 (-1.12%)
After Hours:$15.82-0.08 (-0.50%)
Ultragenyx Pharmaceutical Inc. (RARE)
R&D Expenses
$711.00M
TTM · Period ending: · USD

RARE R&D Expenses
Latest reported$711.00Mperiod ending
Latest reported$711.00Mperiod ending
RARE R&D Expenses ($4.72M → $711.00M)
Annual R&D Expenses
High-resolution chart · PNG
What is r&d expenses?
Research and development spending.
RARE r&d expenses history
Annual fiscal periods · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 750,000,000 | |
| 697,865,000 | |
| 648,449,000 | |
| 705,789,000 | |
| 497,153,000 | |
| 412,084,000 | |
| 357,355,000 | |
| 293,998,000 | |
| 231,644,000 | |
| 183,204,000 | |
| 114,737,000 | |
| 45,967,000 | |
| 27,829,000 | |
| 12,641,000 | |
| 4,717,000 |
Explore More
RARE Financial Metrics
Explore 130+ historical metrics & ratios
Stock Comparison
Compare equities side by side
52-Week Highs Breakout
Stocks breaking to new annual highs
52-Week Lows Oversold
S&P 500 oversold value screener
Trending Momentum
Relative strength momentum leaders
Earnings Calendar
Upcoming earnings dates & reports
S&P 500 Screener
Filter and sort all 500 stocks
Market Movers
Today's biggest gainers and losers
Market Heatmap
Visual sector performance